AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
Nellie K McDanielMari IidaKwangok P NickelColin A LonghurstSamantha R FischbachTamara S RodemsCarlene A KranjacAmber Y BoQianyun LuoMeghan M GallagherNoah B WelkeKaitlyn R MitchellAlison E SchulzJaimee C EckersRong HuRavi SalgiaSeungpyo HongJustine Y BruceRandall J KimpleDeric L WheelerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Collectively, the studies presented herein suggest that tyrosine 821 of AXL mediates resistance to cetuximab by activation of c-ABL kinase in HNSCC and that targeting of both EGFR and c-ABL leads to a robust antitumor response.